WAKIX has been studied in 3 clinical trials in adults with narcolepsy and 1 clinical trial in children 6-17 years old with narcolepsy.
In the clinical trials in adults with narcolepsy, WAKIX significantly reduced excessive daytime sleepiness (EDS) and the number of cataplexy attacks compared with placebo (sugar pill). In the clinical trial of children 6-17 years old with narcolepsy, WAKIX significantly reduced EDS compared with placebo.
